Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT02706626
Title Trial of Brigatinib After Treatment With Next-Generation ALK Inhibitors
Recruitment Terminated
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Criterium, Inc.
Indications
Therapies
Age Groups: senior | adult
Covered Countries USA

Facility Status City State Zip Country Details
University Of Colorado Denver Colorado 80045 United States Details
Duke University Durham North Carolina 27710 United States Details
Vanderbilt Unversity Medical Center Nashville Tennessee 37203 United States Details
University of Texas, Southwestern Dallas Texas 75390 United States Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field